Smith-Magenis syndrome results from heterozygous deletion of chromosome 17p11.2, encompassing the RAI1 gene, or from pathogenic variants within RAI1 itself. RAI1 is classified as DEFINITIVE for SMS causation by ClinGen, reflecting the strongest level of gene-disease evidence. Per GeneReviews, genotype-phenotype correlations have been proposed based on the underlying molecular mechanism: individuals with 17p11.2 deletions that include RAI1 tend to exhibit greater cognitive impairment than those with isolated RAI1 point mutations, reflecting the contribution of haploinsufficiency of additional genes within the deleted segment. The molecular mechanism field is not certified in the current packet beyond what GeneReviews documents. The deletion typically arises as a de novo event, per GeneReviews genetic counseling content, though the inheritance field is not certified in this packet.

Per GeneReviews, no consensus clinical diagnostic criteria for Smith-Magenis syndrome have been formally published. The syndrome is suspected in individuals who present with the combination of a subtly distinctive and evolving facial appearance, intellectual disability, behavioral abnormalities including self-injurious behaviors, and a characteristic sleep disorder. GeneReviews identifies chromosomal microarray analysis as the primary confirmatory tool for detecting 17p11.2 deletions, which captures both typical and atypical deletion sizes. Fluorescence in situ hybridization (FISH) targeting 17p11.2 has historically been used but may miss smaller deletions or atypical boundaries. In cases with clinical features suggestive of SMS but negative microarray results, sequencing of the RAI1 gene is performed to identify pathogenic point variants. The diagnostic methods field is not certified in the current packet beyond GeneReviews guidance.

No treatments are specifically FDA-approved for Smith-Magenis syndrome. Per GeneReviews, there is no cure for SMS; care centers on supportive interventions designed to improve quality of life, maximize function, and reduce complications across the lifespan. Multidisciplinary management is the standard approach, involving specialists in neurology, behavioral health, sleep medicine, orthopedics, ophthalmology, and otolaryngology, among others. GeneReviews describes the sleep disorder — driven by an inverted melatonin circadian rhythm — as a primary management target. Melatonin has received orphan drug designation for the treatment of SMS in combination with a beta-blocker; this designation is investigational and does not indicate FDA approval. GeneReviews notes that psychoactive medications for sleep management and behavioral challenges have been used with mixed response, with no single regimen having demonstrated consistent efficacy and adverse reactions having been observed in some individuals. A GeneReviews section on agents to avoid is available, reflecting the particular sensitivity of this population to certain psychoactive compounds.

The long-term course of Smith-Magenis syndrome is shaped by the severity of intellectual disability, the degree of behavioral challenges including self-injurious behaviors, and the extent of sleep disruption. GeneReviews documents more than 400 individuals with deletion or pathogenic RAI1 variants and describes a clinically recognizable phenotype that persists and evolves across the lifespan. The behavioral and sleep manifestations typically continue into adulthood, with adults requiring ongoing multisystem surveillance and supportive care per GeneReviews guidance. GeneReviews describes genotype-phenotype correlations suggesting that individuals with the larger chromosomal deletion tend to experience greater cognitive impact than those with isolated RAI1 point mutations. Formal life expectancy data are not specified in the current packet, and the natural history field is not certified here.

No active clinical trial records are included in the current packet for Smith-Magenis syndrome. GeneReviews references ClinicalTrials.gov and the EU Clinical Trials Register as resources for current study listings, and notes that there may not be ongoing clinical trials for this disorder at any given time. Research interest centers on the role of RAI1 in chromatin remodeling and transcriptional regulation, as well as on the characteristic circadian rhythm abnormality and its pharmacological management. Melatonin-based regimens remain under active investigation, as reflected in the orphan drug designation for a melatonin-plus-beta-blocker combination. The PRISMS patient registry and advocacy network has supported natural history research and published management guidelines referenced by GeneReviews.